ArriVent BioPharma entered into a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals for ARR-002 in Greater China. The deal includes up to $80.6 million in potential payments, comprising an upfront sum and milestone-based amounts, plus mid-single digit to low double-digit tiered royalties on net sales. ArriVent retains global rights outside the region and will supply initial clinical study material. Concurrently, the company reported second quarter 2026 financial results showing a net loss of $93.2 million for the six months ended June 30, 2026, compared to $95.8 million in the prior year period. Cash and investments totaled $373.1 million as of June 30, 2026, expected to fund operations into 2028. ArriVent BioPharma is a clinical-stage biopharmaceutical company developing innovative cancer therapeutics.